Real-time US stock institutional ownership tracking and fund flow analysis to understand who owns and is buying the stock. We monitor 13F filings and institutional buying patterns because large investors often have superior information.
Lantern Pharma Inc. (LTRN), a clinical-stage biotech firm focused on AI-driven oncology therapeutic development, is trading at a current price of $1.61 as of 2026-04-06, marking a -0.68% change in the most recent trading session. This analysis outlines key technical levels, recent market context, and potential near-term scenarios for LTRN, as the stock has traded in a tight range in recent weeks with limited fundamental catalysts available to investors as of this month. No recent earnings data i
Is Lantern Pharma (LTRN) Stock Worth Buying Now | Price at $1.61, Down 0.68% - Rating Change
LTRN - Stock Analysis
3694 Comments
761 Likes
1
Santita
Active Reader
2 hours ago
Expert US stock short interest and short squeeze potential analysis for identifying high-risk high-reward opportunities. Our short interest data helps you understand bearish sentiment and potential catalysts for short covering rallies.
👍 126
Reply
2
Crishawn
Expert Member
5 hours ago
Free US stock growth rate analysis and revenue trajectory projections for identifying fast-growing companies. Our growth research helps you find companies with accelerating momentum that could deliver exceptional returns.
👍 123
Reply
3
Zoiee
Elite Member
1 day ago
This deserves a spotlight moment. 🌟
👍 34
Reply
4
Kaisei
Influential Reader
1 day ago
The market demonstrates resilience, with selective gains offsetting minor losses in other areas.
5
Nelvia
Engaged Reader
2 days ago
Great analysis that doesn’t overwhelm with unnecessary detail.
👍 191
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.